Page IH, Berrettoni AB, Sones FM: Prediction of coronary heart disease based on clinical suspicion, age, total cholesterol and triglyceride. Circ42:625, 1970.
3.
Banks DC, Raftery EB, Oran S.: Clinical significance of coronary arteriogram. Br Heart J33:863, 1971.
4.
Oliver M.: Dietary cholesterol, plasma cholesterol and coronary heart disease. Br Heart J38:214, 1976.
5.
Connor WE, Connor SL: The key role of nutritional factors in the prevention of coronary heart disease . Prev Med1:49, 1972.
6.
Nitter-Hauge S., Enge I.: Relation between blood lipid levels and angiographically evaluated obstructions in coronary arteries. Br Heart J35:791, 1973.
7.
Nash DT, Gensini GG, Arno T., et al: The Erysicthon Syndrome, accelerated vascular disease due to dietary induced hyperlipidemia. Circ56:363, 1978.
8.
Nash DT: The Erysichthon Syndrome: Progressive coronary artery disease. Obesity and Bariatric Med8:88, 1979.
9.
Jones DH, Greenwood RH, Mahler RF: A new lipid lowering agent gemfibrozil. Clin Trials J 2:42, 1976.
10.
Dahlen D., Gillnas T.: Effect of gemfibrozil on serum lipid levels. Artery7:224, 1980.
11.
Eisalo A., Manninen V.: A long term trial of gemfibrozil in the treatment of hyperlipidemia. Pro Roy Soc Med69:49, 1976.
12.
Nye ER, Sutherland Nhf, Temples WA: The treatment of hyperlipoproteinemia with gemfibrozil compared with placebo and clofibrate. New Zealand Med J92:345, 1980.
13.
Manninenm V. , Malkonen M., Tuomilehlo J.: Treating lipid disorders. Am Heart J97:674, 1979.
14.
Carew TE, Kochinsky T., Hayes SB, Steinberg D.: A mechanism by which high density lipoproteins may slow down the atherogenetic process. Lancet1315, 1976.
15.
Small DM: Cellular mechanisms for lipid deposition in atherosclerosis. NEJM297:873, 1977.
